Agere Augments Leadership with Pharmaceutical Manufacturing and Supply Chain Expert

Agere Augments Leadership with Pharmaceutical Manufacturing and Supply Chain Expert

Solubility CDMO Adds VP to Head cGMP Manufacturing Operations

BEND, Ore.--(BUSINESS WIRE)--Agere Pharmaceuticals, Inc., a leading oral bioavailability contract development and manufacturing organization (CDMO), announced today that Mr. Michael R. Deperro has joined the company as VP of Operations. The company added cGMP manufacturing capabilities in 2011, and since has expanded facilities to produce Phase I through Phase IIb clinical trials materials for clients.

"Mike brings Agere extensive experience and a strong track record for successfully managing and growing cGMP operations"
"Mike brings Agere extensive experience and a strong track record for successfully managing and growing cGMP operations," commented Marshall Crew, President and CEO of Agere. "He will play a key role as we continue our rapid growth to meet the rigorous expectations of our clients."

Mr. Deperro has held director and GM-level manufacturing positions at numerous pharmaceutical companies including Alkermes (NASDAQ: ALKS) and Taro Pharmaceuticals (NYSE: TARO). He has also been responsible for implementing research and manufacturing infrastructure and operations domestically and abroad for large pharmaceutical and biotechnology companies including Merck and Co. (NYSE: MRK) and Novartis (NYSE: NVS). Mr. Deperro's career focus has been in the areas of drug development, new product launch, and commercialization. His regulatory compliance knowledge of FDA, MHRA, PMDA and ANVISA agencies enhances Agere's strength in meeting the needs of a growing international client base. Mr. Deperro holds the Bachelor of Science degree in Mechanical Engineering from Notre Dame University, and has earned the Six Sigma Yellow Belt status from the International Society for Six Sigma Certifications.

For information about Mr. Deperro and Agere, please visit www.agerepharma.com.

About Agere

Agere is a leading CDMO focused on improving the oral bioavailability of insoluble APIs. The company supports clients from formulation design and development through cGMP manufacturing for Phase I through Phase IIb clinical trials. Agere is expert in solid dispersion techniques and in a broad selection of solid dosage forms. The company is recognized for its solubilization knowledge and use of fundamental science and novel technologies to achieve best outcomes for clients. All services are delivered on a fee-for-service basis, and every project is customized to overcome the specific challenges associated with each insoluble compound. Agere is located in Bend, OR. www.agerepharma.com.

©2013 Agere Pharmaceuticals, Inc. Agere Pharmaceuticals is a trademark of Agere Pharmaceuticals, Inc.

Contacts

Agere Pharmaceuticals, Inc.
Casey Jones, +01-702-994-0605
[email protected]

Suggested Articles

Q32 Bio raised $60 million to push its lead antibody through the clinic and bolster its pipeline and the technology behind it.

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.